이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Comprehensive Lung Health (CLUES)

2026년 11월 6일 업데이트: Ankit Bharat, Northwestern University

Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification

Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

10000

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Northwestern Medicine
        • 수석 연구원:
          • Ankit Bharat, MD
        • 연락하다:
        • 부수사관:
          • Momen Wahidi, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

All Cohorts:

•Adults 21 through 85 years of age.

Cohort 1:

•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.

Cohort 2:

•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.

Cohort 3:

  • Asymptomatic individuals who:
  • Do not have a clinical indication for chest CT
  • Do not meet current USPSTF criteria for LDCT lung cancer screening
  • Able to provide informed consent

Exclusion Criteria:

All Cohorts:

•Individuals below the age of 21 and above the age of 85.

Cohort 3:

  • Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
  • Any chest CT within the prior 2 years
  • Pregnancy
  • In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
  • Unable to provide informed consent or lacks decision-making capacity
  • McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 상영
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Cohort 1 (Medical Indication Group)

Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

간섭 없음: Cohort 2 (Guideline-Based Screening Group)

Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

활성 비교기: Cohort 3 (Asymptomatic Research LDCT Group)

Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study.

A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.

다른 이름들:
  • LDCT

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary Endpoint
기간: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

2차 결과 측정

결과 측정
측정값 설명
기간
Secondary Endpoint 1
기간: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 2
기간: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 3
기간: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 4
기간: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Associations between baseline defined variables and LDCT-detectable findings.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 5
기간: 5 years

EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available.

5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory Endpoint 1
기간: 6 years

Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories.

6 years
Exploratory Endpoint 2
기간: 6 years

Exploratory prediction models if event counts support model development.

6 years
Exploratory Endpoint 3
기간: 6 years

Descriptive analyses of downstream clinical evaluation after baseline CT findings.

6 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Ankit J Bharat, MD, Northwestern Medicine Canning Thoracic Institute
  • 수석 연구원: Momen J Wahidi, MD, Northwestern Medicine Canning Thoracic Institute

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 16일

기본 완료 (추정된)

2030년 9월 16일

연구 완료 (추정된)

2031년 12월 30일

연구 등록 날짜

최초 제출

2026년 11월 6일

QC 기준을 충족하는 최초 제출

2026년 11월 6일

처음 게시됨 (실제)

2026년 11월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 6일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • STU00223477

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .